-
Gilead Sciences Halts Development of Magrolimab for HR-MDS Following Phase III Trial Results
•
Gilead Sciences (NASDAQ: GILD) has decided to stop pursuing the potential first-in-class immunotherapy, magrolimab, for higher-risk myelodysplastic syndromes (HR-MDS) after obtaining disappointing efficacy data from a Phase III trial. Although the company has not yet released the results, it has confirmed that the study’s primary endpoints included complete response (CR)…
-
EU Commits EUR 3 Million to Strengthen Healthcare Access in Latin America and Caribbean
•
The European Union (EU) has announced a EUR 3 million (USD 3.3 million) funding injection into a partnership with Latin America and the Caribbean, launched last year to strengthen healthcare access. This initiative aims to bolster the development and manufacturing of vaccines, medicines, and other health technologies to combat diseases…
-
AbbVie’s Aquipta and Novartis’s Piqray Receive Regulatory Approvals in Mexico
•
Mexico’s Federal Commission for Protection against Health Risks (COFEPRIS) has granted registration approvals to two innovative drugs: AbbVie’s (NYSE: ABBV) analgesic Aquipta (atogepant) and Novartis’ (NYSE: NVS) cancer therapy Piqray (alpelisib). This marks a significant milestone for both companies, expanding access to these treatments in the Mexican market. Aquipta: A…
-
Oxford and Peking University Study Unveils Genetic Risk Factors in East Asian Population
•
Researchers from the UK’s Oxford Population Health and China’s Peking University have conducted a comprehensive study analyzing genetic data from a large Chinese population, shedding light on genetic risk factors for diseases such as diabetes, stroke, depression, and chronic respiratory disease. The study aims to provide valuable data for drug…
-
Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment
•
Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam (NASDAQ: ALNY), securing rights to co-develop and co-commercialize Alnylam’s zilebesiran, a Phase II stage RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension. Financial Terms and Collaboration DetailsUnder the agreement, Roche will pay Alnylam…
-
Pfizer Ends Partnership with Syros Pharmaceuticals for Sickle Cell Disease Program
•
Syros Pharmaceuticals Inc., (NASDAQ: SYRS) has disclosed in an SEC filing that Pfizer (NYSE: PFE) has decided to terminate a partnership previously established between Syros and Global Blood Therapeutics Inc., (GBT). Pfizer’s decision came after it acquired GBT for USD 5.4 billion in October 2022, taking over the existing deal.…
-
Ascletis Pharma’s ASC22 Combo Therapy Shows Promise in HIV Functional Cure Clinical Trial
•
China-based Ascletis Pharma Inc., (HKG: 1672) has announced that the Shanghai Public Health Clinical Center presented clinical results of ASC22 (envafolimab) in combination with chidamide as a novel combination therapy aimed at achieving a functional cure for human immunodeficiency virus (HIV) infection. The findings were showcased at the 12th International…
-
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for a combination therapy involving its adebrelimab (SHR-1316) with Hansoh Pharmaceutical Group Co., Ltd’s (HKG: 3692) Ameile (almonertinib) or SHR-A2009, with or without chemotherapy, for the treatment…
